How much does REBLOZYL (Luspatercept for Injection) Cost& price without insurance in China?
REBLOZYL® is the commercial brand name of Luspatercept for Injection, developed by Bristol Myers Squibb. It is a first-in-class erythroid maturation agent. It binds to transforming growth factor superfamily ligands to improve late-stage erythroid progenitor cell maturation, reduce ineffective erythropoiesis and lower long-term red blood cell transfusion demands in anemic patients with hereditary or myeloid blood disorders.
Main Indications
Treatment of adult patients with β-thalassemia who require regular red blood cell transfusions with transfusion volume ≤15 units per 24 weeks;
Treatment of anemia in adult patients with very low-, low- and intermediate-risk myelodysplastic syndromes who rely on regular red blood cell transfusions.
Clinical Research
Global multicenter pivotal trials fully validated its transfusion-reduction efficacy for chronic transfusion-dependent anemic patients;
β-thalassemia registration trials confirmed sustained reduction in monthly red blood cell transfusion requirements and improvement of iron overload status;
MDS cohort observational studies demonstrated stable hemoglobin elevation and prolonged transfusion intervals for low-risk myelodysplastic patients;
Dose-response comparative research identified optimal subcutaneous dosing cycles with balanced efficacy and tolerability;
Long-term follow-up trials verified controllable bone pain, headache and other mild adverse reactions during chronic maintenance therapy.
Common Side Effects
Common mild adverse reactions: Bone pain, headache, arthralgia, fatigue, dizziness and mild injection site erythema;
Laboratory abnormalities: Rare transient mild elevation of blood pressure;
Severe but uncommon risks: Hypertension crisis, thromboembolic events, severe hypersensitivity and tumor progression risk in MDS patients.
Approval Status in China
REBLOZYL® (specification 25mg per vial, only for subcutaneous injection after reconstitution) obtained NMPA conditional approval in January 2022 and was officially launched in June 2022. It is a prescription injectable rare hematological drug included in China’s Category B medical insurance catalogue.
Buy REBLOZYL (Luspatercept for Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
